The role of interventional pulmonology in endobronchial metastasis of renal cell carcinoma

Deniz DOĞAN¹
Demet TURAN²
Mehmet Akif ÖZGÜL²
Erdoğan ÇETİNKAYA²

¹ Department of Chest Diseases, University of Health Science, Gülhane Training and Research Hospital, Ankara, Turkey
² Sağlık Bilimleri Üniversitesi, Yedikule Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Gülhane Eğitim ve Araştırma Hastanesi, Gülhane Eğitim ve Araştırma Hastanesi, Ankara, Türkiye

ABSTRACT

The role of interventional pulmonology in endobronchial metastasis of renal cell carcinoma

Introduction: Although metastasis of extrapulmonary solid organ malignant tumors to the lungs is very common, endobronchial metastases are very rare. The most common extrapulmonary tumors that make endobronchial metastases are breast, kidney and colorectal carcinomas.

Materials and Methods: In this study, we retrospectively examined the data of eleven renal cell carcinoma patients who underwent endobronchial metastases in an eight-year period.

Results: Ten of the patients were male and the mean age was 55 ± 1 (41-71) years. The most common symptom was cough (45.5%, n= 5), on the other hand 18.2% (n= 2) of the patients had no complaints. Right bronchial system, left bronchial system and tracheal distribution rates of endobronchial lesions were 45.5% (n= 5), 63.6% (n= 7) and 27.3% (n= 3) respectively. The mean time from diagnosis of primary renal cell carcinoma to endobronchial metastases was 47.5 ± 32 (5.2-100.5) months. A total of twenty two interventional procedures were performed. All except one patient underwent endobronchial treatment. Argon plasma coagulation was most commonly used as the endobronchial metastases option (n= 10, 100%). The mechanical resection (n= 6, 60%), laser (n= 5, 50%), cryoextraction (n= 5, 50%) and cryotherapy (n= 4, 40%) methods were used other than argon plasma coagulation. The mean survival time was 19.4 ± 15.7 (3.2-40.5) months after endobronchial metastases and 54.0 ± 40.4 (8.7-107.6) months after renal cell carcinoma diagnosis.

Cite this article as: Doğan D, Turan D, Özgül MA, Çetinkaya E. The role of interventional pulmonology in endobronchial metastasis of renal cell carcinoma. Tuberk Toraks 2019;67(3):211-8.
INTRODUCTION

Endobronchial metastasis (EBM) is very rare, although pulmonary metastasis is very common in extrapulmonary solid organ malignancies. EBM frequency ranges from 2 to 28% (1,2). The most common cancers that cause EBM are breast, kidney and colorectal carcinomas (3-5). 20-30% of patients with renal cell carcinoma (RCC) have metastases at diagnosis and the most common distant metastatic site is lung parenchyma (6-8). At the same time, RCC is the most common extrathoracic tumor metastasizing to the central airway (1). Despite being the most common tumor with EBM, there are no large series in the literature and they are generally referred to as case reports. Currently, there is still no elaborate treatment for RCC tumors with EBM. In this study, we aimed to determine the general characteristics, endobronchial therapy (EBT) options and survival times of RCC patients with EBM.

MATERIALS and METHODS

Eleven patients with RCC who underwent EBM between January 2009 and December 2016 in a tertiary education and research hospital interventional bronchology unit were retrospectively screened. The demographic features such as age and sex of the patients, and the presence of primary RCC were recorded. Distribution of endobronchial (EB) lesions in the bronchial system and airway stenosis rates, applied EBT methods/frequency, complications due to treatment, and average life expectancy after EBT were analyzed. Airway stenosis due to EB lesion is classified in three groups. 1) Mild stenosis (≤ 50% stenosis), 2) Moderate stenosis (51%-70% stenosis), 3) Severe stenosis (≥ 71% stenosis). Rigid bronchoscopic procedures (Karl Storz, Germany) were performed under general (total intravenous anesthesia) anesthesia. General anesthesia induction was achieved with midazolam 0.05-0.1 mg/kg, propofol (maximum dose 1000 mg), remifentanil (maximum dose 2 mg) and rocuronium (maximum dose 50 mg) considering the patient’s condition. We did not encounter any side-effects or complications due to anesthesia. Approval for the study was granted by the Scientific Board Committee of Yedikule Chest Diseases and Chest Surgery Training and Research Hospital (08.10.2018).

RESULTS

Eleven patients (10 male, 1 female) with EB metastasis of RCC were undergone interventional rigid bronchoscopic procedures. The mean age of the patients was 55 ± 1 (41-71) years. Of 11 patients nine were known to have RCC prior to EBT (metachronous cases), and in the remaining two patients EB tumoral lesion was detected as an initial finding without any extrapulmo-
nary tumor (anachronous cases). The time from the detection of primary RCC to the occurrence of EBM was 47.5 ± 32 (5.2-100.5) months in the whole population. The most common symptom of the patients was cough (45.5%, n= 5). Other symptoms were dyspnea (36.4%, n= 4), hemoptysis (27.3%, n= 3) and chest pain (9.1%, n= 1) and the rate of patients without any symptoms was 18.2% (n= 2). Of total 11 patients one had mild, one had moderate and nine had severe airway stenosis. We couldn’t reach the initial RCC diagnosis in the of nine patients who were known to have RCC prior to EBM diagnosis. One of these patients applied to our clinic with right total atelectasis. His interventional rigid bronchoscopy revealed a right EB lesion that was totally obstructed the right main bronchus. He was thought to be not eligible for EBT and the procedure was terminated after getting forceps biopsies. The histopathological examination of these biopsies formerly revealed RCC metastasis. This patient died 11 days after the biopsy because of severe respiratory failure due to the progression of the primary disease. Only demographic data of this patient was used in this study. The demographic characteristics, treatment modalities and survival rates of all patients are summarized in Table 1. A total of 22 invasive rigid bronchoscopic procedures were performed. In all cases, interventional procedures were performed by rigid bronchoscopy under IV total anesthesia and the number of interventional procedures per case was 2.0 ± 1.1. In five of 11 patients, only one session was performed, while in six, multiple interventional procedures were needed. Patients who developed early metastasis frequently underwent one session while patients with late metastasis underwent multiple sessions. Both general (47.9 ± 5 vs. 57 ± 4 months) and post-EBM survival (14.6 ± 2 vs. 18.2 ± 1) were shorter in the patients that required multiple sessions of interventional EBT procedures. In 90.9% of the patients (n= 10), the level of bronchial stenosis was severe. EBT was performed all except one patient. Argon plasma coagulation (APC), laser, cryoextraction, and mechanical resection methods were used as EBT procedures. In four patients cryotherapy was used to the residual tissue after EBT (Table 2). The most common method was APC and was used in all patients. The most common method after APC was mechanical resection and was used in 60% of patients. Two patients underwent stenting after EBT. One patient with a tracheal lesion had a flat silicone stent, another patient with a left main bronchus lesion had a silicone Y stent. Both patients who had stents were treated with EBT for four times. A patient was stuck with a Y stent for the first time after 6.5 months with a relapse. Approximately five months later, migraine and mucostasis complications were seen, but there was no need to remove the stent. The other patient underwent tracheal plain silicone stent implantation in the second session and about four months later the patient’s own stent was removed. Complications were seen in four patients due to perioperative endobronchial treatment. These were necessity of follow-up in intensive care unit due to arrhythmia in one patient, prolonged hemorrhage in one patient and prolonged intubation in two patients. Endobronchial treatment was associated with no mortality in the early period. EB lesions were observed in 45.5% (n= 5) of the right bronchial system and 63.6% (n= 7) of the left bronchial system, and 27.3% (n= 3) of the trachea were observed (Table 3). One patient with tracheal involvement had tracheal and right main bronchus involvement, one patient had trachea, right main bronchus and left main bronchus involvement, and only the last patient had tracheal involvement. The mean duration of metachronous tumors in these three patients was 55.5 ± 40 (30.8-100.5) months. The mean survival time after EBM was 19.4 ± 15.7 (3.2-40.5) months and the mean life span of the whole population after RCC diagnosis (RCC diagnosis-ex) was 54.0 ± 40.4 (8.7-107.6) months.

**DISCUSSION**

Lung is the most common metastatic cite of RCC. It is also a non-thoracic solid tumor that most commonly metastasizes to the EB system. In the literature, there is a lack of published reports regarding the endobronchial metastases of the RCC. Most of them are generally case reports or limited series of cases (9-16). Metastases to the endobronchial system of RCC are often seen as metachronous cases (11). In our study, 82% of our patients (9 out of 11 patients) were diagnosed as primary RCC before EBM. Our two patients were first presented with endobronchial findings (anachronous cases). In the literature, the duration from the primary diagnosis of extra pulmonary tumors to the development of the EBM was reported at rates ranging from 36 months to 136 months, while there is not enough data on RCC (4,9,11,17,18). Literature data often include case reports and publications in the form of systemic review. Alessandro et al. (11) evaluated the data of 174 EBM patients retrospectively during the 18-year period and reported the average time from primary diagnosis to EBM in patients with
Table 1. Patients characteristics.

| Case no | Age/Sex | Location                          | No. of treatments | APC  | Laser | Cryotherapy | Cryoextraction | MR  | Stent | Interval (month) | Survival-1 (month) | Survival-2 (month) |
|---------|---------|-----------------------------------|-------------------|------|-------|-------------|-----------------|-----|-------|----------------|--------------------|--------------------|
| 1       | 56/M    | Left upper lobe bronchus          | 1                 | +    | -     | -           | -               | -   | -     | 63.87          | 101.1              | 37.23              |
| 2       | 68/M    | Left main bronchus               | 1                 | +    | +     | +           | +               | +   | -     | Not known      | Not known          | 40.5               |
| 3*      | 71/M    | Right main bronchus              | 1                 | -    | -     | -           | -               | -   | -     | Not known      | Not known          | -                  |
| 4       | 65/M    | Left main bronchus               | 4                 | +++  | -     | +           | -               | +   | +     | 0**            | 16.43              | 16.43              |
| 5       | 41/M    | Trachea                          | 4                 | ++   | -     | -           | -               | +   | +     | 100.5          | 107.57             | 7.07               |
| 6       | 54/M    | Intermedier bronchus             | 1                 | +    | -     | -           | -               | -   | -     | 5.17           | 8.67               | 3.50               |
| 7       | 43/M    | Left main and left upper lobe bronchus | 2       | +    | +     | -           | -               | +   | -     | 28.47          | 68.14              | 39.67              |
| 8       | 50/M    | Trachea and right main bronchus  | 1                 | +    | +     | +           | +               | -   | -     | 30.8           | 34.03              | 3.26               |
| 9       | 45/F    | Left main bronchus               | 2                 | ++   | -     | -           | +               | -   | -     | 68.43          | 96.86              | 28.43              |
| 10      | 55/M    | Trachea, right and left main bronchus | 3         | ++   |+++    | ++          | +               | +   | -     | 35.1           | 43.40              | 8.30               |
| 11      | 57/M    | Right main bronchus              | 2                 | ++   | -     | -           | -               | +   | +     | 0**            | 9.53               | 9.53               |
| Mean    |         |                                   |                   | 2.0  | 1.45  | 0.63        | 0.45            | 0.5 | 0.54  | 47.5 ± 32      | 54.0 ± 40.4        | 19.4 ± 15.7        |

* Case 3 was not suitable for endobronchial therapy, we therefore only used its demographic data's.
** Patients diagnosed with renal cell carcinoma by endobronchial biopsy (anachronous cases).
Interval: Interval between renal cell carcinoma and endobronchial biopsy.
Survival-1: Interval between diagnosis of renal cell carcinoma and mortality.
Survival-2: Interval between endobronchial metastasis and mortality.
APC: Argon plasma coagulation, MR: Mechanical resection.
renal carcinoma as 82 (17.47-147.27) months. Sorensen reported the duration of EBM of 34 kidney-derived tumors as 35 (0-114) months after English literature scan from 1962 to 2002 (17). In our patient population, the mean time from primary RCC to EBM was 47.5 ± 32 (5.2-100.5) months. In our study, endobronchial lesions were mostly found in the left bronchial system. The rates of left bronchial system, right bronchial system and tracheal involvement were 63.6% (n= 7), 45.5% (n= 5) and 27.3% (n= 3) respectively. In the literature, we could not reach any data on the distribution of RCC metastases in the endobronchial system. However, when looking at the endobronchial metastases of extrapulmonary solid malignancies, Sorensen found that both bronchial systems were equally held (41% vs. 41%), Kiryu et al. reported right bronchial involvement by 80% (4,17). Tracheal metastasis of extrapulmonary solid tumors are seen in about 4% (17). In a systematic review Madariaga et al. searched the published English literature between 1978 to 2017 (10). They found that the most common extra-thoracic primary tumors were colon and kidney. The authors reported that the RCC had the longest metachronous tumor development time with an average of 90.0 (48.0-204.0) months in this study. Tracheal involvement was observed in three patients in our patient population. The mean duration of onset of metachronous tumors in these patients was 55.5 ± 40 (30.8-100.5) months. In the absence of tracheal involvement, this time was shorter and the average was 41.5 ± 30 (5.2-68.4). Five and ten year survival rates of RCC after curative resection of pulmonary metastasis are 40% and 33%, respectively (19). Metastasectomy is the most prominent treatment method in selected cases because the mean survival time is as short as 10 months in cases of untreated metastatic RCC (20). However, there is no accepted treatment option for endobronchial metastases of RCC. Different EBT techniques have been applied in endobronchial RCC metastases in the literature including laser therapy, cryotherapy and electrosurgery snaring. In cases with tumor-induced bronchial obstruction, these treatment modalities are not curative but provide excellent palliation and a positive contribution to the survival of EBTs (13,14,16,21-25). These treatment approaches are often chosen and present as a viable option in cases with bronchial tumor obstruction. All of our patients underwent rigid bronchoscopy under IV total anesthesia and the mean number of interventional procedures per procedure was 2.0 ± 1.1. Except one patient who was not eligible for endobronchial therapy, the entire study population underwent EBT. The most common used EBT procedure was APC. The other options for locating and characterizing the EB tumors were laser, cryoextraction cryotherapy, and mechanical resection. In our study, overall survival (47.9 ± 5 vs. 57 ± 4 months) and survival after EBT (14.6 ± 2 vs. 18.2 ± 1 months) were shorter in patients requiring multiple sessions of intervention for EBT. This can be explained by the necessity of multiple endoscopic interventions due to excessive tumor volume or the tumor aggressivity. In this regard it is known that tumor volume is negatively correlated with life expectancy (26). Because of endobronchial tumor stenosis caused by extrapulmonary malignancies, stent applications for palliation can also be performed. This method is frequently applied for strictures due to esophagus and thyroid cancers (27-31). Because of the close proximity of the

| Locations | Number of patients (%) |
|-----------|------------------------|
| Trachea   | 3                      |
| Right     |                         |
|           | Main bronchus           | 4 |
|           | Intermedier bronchus    | 1 |
|           | Intermedier bronchus    | 1 |
| Left      |                         |
|           | Main bronchus           | 5 |
|           | Upper lobe bronchus     | 2 |

Table 2: Techniques of endobronchial therapy

| Bronchoscopic therapy | Number of patients (%) |
|-----------------------|------------------------|
| APC                   | 10 (100)               |
| Mechanical resection  | 6 (60)                 |
| Laser                 | 5 (50)                 |
| Cryoextraction        | 5 (50)                 |
| Cryotherapy           | 4 (40)                 |

APC: Argon plasma coagulation.
esophagus and thyroid malignancies, airway invasion can be seen more frequently. In addition, literature refers stent applications for colorectal, hepatocellular and breast cancers with EBM (32-34). Migration, formation of granulation tissue, mucostasis and fistula development are the most frequent complications in stent applications and care must be taken in terms of these complications (35). Stent applications may be performed after resection in RCC metastases. In our patient population, two patients underwent stent implantation. Approximately five months after stent insertion, complications of thrombosis and mucostasis were observed in the first patient, but no stent removal was required. The other patient had no complication, but four months later the stent was removed due to the request of the patient. The incidence of invasive bronchoscopic treatment varies from 1.6 to 11.0% in the literature, and the mortality rates due to treatment are reported to be 0.8 to 3.0% (36). These general complications include massive hemorrhage, endobronchial burns (in hot methods), failure in sufficient airway opening, asphyxia, tracheoesophageal fistula, mediastinal emphysema, pneumothorax, transient desaturation, chest pain, bronchospasm, atelectasis, airway laser, bronchial rupture, cardiac arrhythmia. In our patient population, there were only four complications associated with endobronchial treatment during the perioperative period. These were arrhythmia in one patient, prolonged hemorrhage in one patient, and need of extended intensive care unit due to prolonged intubation in two patients. No perioperative mortality was observed secondary to endobronchial treatment. In the literature, there are various literature data on the mean survival of non-small cell lung tumors after EBM. In general, although it depends on the biological behavior of the primary tumor, the mean survival time is usually short (37). Sorensen, in his study scanning English Medical Sources between 1962 and 2002, reported a median survival time of 204 patients as 15.2 (0-150) months after EBM (17). Similarly, in his series of 16 patients, Kiryu et al. reported the survival time as 15.5 months (4). A total of 43 diseases were present in a more current series, Lee et al. (9) reported mean survival after EBM as 16.1 (0-59) months (9). Although there is not enough data on survival time after EBM of kidney tumors in the literature, Heitmiller et al. reported that the RCC is associated with longer survival rates than other tumor metastases (38). In another study, Sorensen evaluated the data of 204 metastatic disease for more than 40 years (17). In his study 34 patients had EB metastasis of RCC and their survival time after EBM diagnosis was 20 (0-150) months. In our study, mean survival was 19.4 ± 15.7 (3.2-40.5) months after EBM. This value is consistent with Sorensen’s data, and as mentioned above, is longer than the survival times of other tumor metastases. Therefore, given the current literature data and the findings in our study, the use of endobronchial treatments may be recommended in the presence of EBM due to RCC, if necessary in selected cases, including aggressive treatments. Because of the low complication rates of the EBT options, multiple interventional sessions are acceptable and safe with minimal additional complication rates. Although endobronchial treatments are not curative in most cases, endobronchial tumor tissue should be resected. We shouldn’t hesitate to perform multiple sessions in this patient group.

The most important limitations of our study were the small sample size and the retrospective design. Although these limitations we achieved some invaluable results that would contribute to the literature. For future high volume prospective studies can strengthen and improve our results.

CONCLUSION

In conclusion, these results suggest that the application of EBT methods may be used as a treatment approach in patients with EB metastasis of RCC, given the benefits of surgical resection of the metastatic lesions to be the best option in RCC patients. In the light of our results, we consider and recommend that EBT options can be performed with low complication rates and with an advantage of survival.

CONFLICT of INTEREST

No conflict of interest declared by the authors.

AUTHORSHIP CONTRIBUTIONS

Concept/Design: DD, EÇ
Analysis/Interpretation: DT, MAÖ
Data Acquisition: DT, MAÖ
Writting: DT, MAÖ
Critical Revision: All of authors.
Final Approval: All of authors.
REFERENCES

1. Braman SS, Whitcomb ME. Endobronchial metastasis. Arch Intern Med 1975;135:543-7.

2. Shepherd MP. Endobronchial metastatic disease. Thorax 1982;37:362-5.

3. Salud A, Porcel JM, Rovirosa A, Bellmunt J. Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol 1996;62:249-52.

4. Kiyru T, Hoshi H, Matsui E, Iwata H, Kokubo M, Shimokawa K, et al. Endotracheal/endobronchial metastases. Chest 2001;119:768-75.

5. Kao HW, Yu CP, Tzao C, Lin WC, Hsu HH, et al. An unusual case of thymic carcinoma with endobronchial metastases manifesting as centrilobular opacities. J Thorac Imaging 2006;21:238-40.

6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-7.

7. Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23:973-80.

8. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 1988;114:605-12.

9. Lee SH, Jung JY, Kim Do H, Lee SK, Kim SY, Kim EY, et al. Endobronchial metastases from extrathoracic malignancy. Yonsei Med J 2013;54:403-9.

10. Madariaga ML, Caisset H. Secondary tracheal tumors: a systematic review. Ann Cardiothorac Surg 2018;7:183-96.

11. Marchioni A, Lasagni A, Busca A, Cavazza A, Agostini L, Migaldi M, et al. Endobronchial metastasis: an epidemiologic and clinicopathologic study of 174 consecutive cases. Lung Cancer 2014;84:222-8.

12. Chan A, Juarez M, Albertson T, Morrissey B, Allen R, Mayers F. Laser treatment of endobronchial renal cell carcinoma. J Bronchol 2004;11:92-7.

13. Noppen M, Meysman M, Van HR, Lamote J, D’Haese J, Vincken W. Bronchosscopic aspects of renal cell carcinoma (RCC). Anticancer Res 1999;19:1567-72.

14. Chan A, Juarez M, Albertson T, Morrissey B, Allen R, Mayers F. Laser treatment of endobronchial renal cell carcinoma. J Bronchol 2004;11:92-7.

15. Milia K, Matsu K, Takamori S, Sueyoshi S, Mitsuoka M, Fujita H. Temporary stenting for malignant tracheal stenosis due to advanced thyroid cancer. Acta Otolaryngol 2003;123:502-7.

16. Schreiber J, Schück R. Curative treatment of an endobronchial metastasis of renal carcinoma by argon plasma coagulation. J Bronchol 2005;12:50-1.

17. Sorensen JB. Endobronchial metastases from extrapulmonary solid tumors. Acta Oncol 2004;43:73-9.

18. Akoglu S, Ucan ES, Cetik G, Sener G, Sevinc C, Kilinc O, et al. Endobronchial metastases from extrathoracic malignancies. Clin Exp Metastasis 2005;22:587-91.

19. Piltz S, Meimarakis G, Wichmann M, Obermeder R, Jauch KW, Furst H. Surgical treatment of pulmonary metastases from renal cancer. Urologe 2003;42:1230-7.

20. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.

21. Dobbertin I, Dierkesmann R, Kwiatkowski J, Reichardt W. Bronchoscopic aspects of renal cell carcinoma (RCC). Anticancer Res 1999;19:1567-72.

22. Sakamoto N, Inafuku S, Shimohi K, Nomura K, Honna K, Kawabata T, et al. Endobronchial metastasis from renal cell carcinoma: report of a case. Surg Today 2000;30:744-6.

23. Themelini D, Duchateau P, Boudaca W, Lamy V. Endoscopic resection of an endobronchial hypernephroma metastasis using a polypectomy snare. Eur Respir J 1990;3:732-3.

24. Chan A, Juarez M, Albertson T, Morrissey B, Allen R, Mayers F. Laser treatment of endobronchial renal cell carcinoma. J Bronchol 2004;11:92-7.

25. Noppen M, Meysman M, Van HR, Lamote J, D’Haese J, Vincken W. Bronchoscoptic cryotherapy: preliminary experience. Acta Clin Belg 2001;56:73-7.

26. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol 2010;28:319-27.

27. Chan KP, Eng P, Hsu AA, Huat GM, Chow M. Rigid bronchoscopy and stenting for esophageal cancer causing airway obstruction. Chest 2002;122:1069-72.

28. Miwa K, Matsu K, Takamori S, Sueyoshi S, Mitsuoka M, Fujita H. Temporary stenting for malignant tracheal stenosis due to esophageal cancer: a case report. Jpn J Clin Oncol 2002;32:27-9.

29. Tsutsui H, Usuda J, Kubota M, Yamada M, Suzuki A, Shibuya H, et al. Endoscopic tumor ablation for laryngotracheal intraluminal invasion secondary to advanced thyroid cancer. Acta Otolaryngol 2008;128:799-807.

30. Tsutsui H, Hoshi M, Kubota M, Suzuki A, Nakamura N, Usuda J, et al. Management of thyroid carcinoma showing thymus-like differentiation (CASTLE) invading the trachea. Surg Today 2013;43:1261-8.

31. Okiror L, Jiang L, Oswald N, Bille A, Rajesh P, Bishay E, et al. Bronchoscopic management of patients with symptomatic airway stenosis and prognostic factors for survival. Ann Thorac Surg 2015;99:1725-30.
32. Nakamura T, Tajima T, Ogimi T, Miyakita H, Nitta M, Myojin K, et al. Expandable metallic stent for endobronchial metastasis from colorectal cancer: reports of 2 cases. Tokai J Exp Clin Med 2017;42:79-84.

33. Hamai Y, Hihara J, Aoki Y, Taomoto J, Kishimoto I, Kobayashi Y, et al. Airway stenting for tracheal obstruction due to lymph node metastasis of hepatocellular carcinoma. Anticancer Res 2013;33:1761-4.

34. Rotolo N, Dominioni L, De Monte L, Conti V, La Rosa S, Imperatori A. Metastasis at a tracheostomy site as the presenting sign of late recurrent breast cancer. Head Neck 2013;35:E359-62.

35. Ranu H, Madden BP. Endobronchial stenting in the management of large airway pathology Postgraduate Medical Journal 2009;85:682-7.

36. Du Rand IA, Barber PV, Goldring J, Lewis RA, Mandal S, Munavvar M, et al. British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax 2011;66(Suppl 3):iii1-21.

37. Katsimbri PP, Bamias AT, Froudarakis ME, Peponis IA, Constantopoulos SH, Pavlidis NA. Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer 2000;28:163-70.

38. Heitmiller RF, Marasco WJ, Hruban RH, Marsh BR. Endobronchial metastasis. J Thorac Cardiovasc Surg 1993;106:537-42.